UCB to Buy Neurona Therapeutics for Up to $1.15B

Dow Jones

Apr 18

By Josh Beckerman

UCB agreed to buy Neurona Therapeutics for up to $1.15 billion, a deal that would add potential epilepsy drug NRTX-1001 to the Belgian company's portfolio.

The agreement includes $650 million upfront and up to $500 million in potential future milestone payments.

UCB expects to close the transaction by the end of the second quarter.

Column Group, a longtime Neurona investor, led a $23.5 million Series A funding announced in late 2015. Other investors have included Fidelity Management & Research Co., UCB Ventures and Alexandria Venture Investments.

In December, South San Francisco-based Neurona presented results from ongoing Phase 1/2 trials evaluating NRTX-1001, a one-time, allogeneic inhibitory interneuron cell therapy for drug-resistant mesial temporal lobe epilepsy. The company said it continued to see durable seizure reduction from a single administration in most subjects.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

April 17, 2026 16:11 ET (20:11 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2628781786"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2628781786\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2628781786?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-18 04:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2628781786","market":"hk","top_or_hot":-1,"title":"UCB to Buy Neurona Therapeutics for Up to $1.15B","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  UCB agreed to buy Neurona <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for up to $1.15 billion, a deal that would add potential epilepsy drug NRTX-1001 to the Belgian company's portfolio. \n</p>\n<p>\n  The agreement includes $650 million upfront and up to $500 million in potential future milestone payments. \n</p>\n<p>\n  UCB expects to close the transaction by the end of the second quarter. \n</p>\n<p>\n  Column Group, a longtime Neurona investor, led a $23.5 million Series A funding announced in late 2015. Other investors have included Fidelity Management &amp; Research Co., UCB Ventures and Alexandria Venture Investments. \n</p>\n<p>\n  In December, South San Francisco-based Neurona presented results from ongoing Phase 1/2 trials evaluating NRTX-1001, a one-time, allogeneic inhibitory interneuron cell therapy for drug-resistant mesial temporal lobe epilepsy. The company said it continued to see durable seizure reduction from a single administration in most subjects. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 17, 2026 16:11 ET (20:11 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UCB to Buy Neurona Therapeutics for Up to $1.15B</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUCB to Buy Neurona Therapeutics for Up to $1.15B\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-18 04:11</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  UCB agreed to buy Neurona <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for up to $1.15 billion, a deal that would add potential epilepsy drug NRTX-1001 to the Belgian company's portfolio. \n</p>\n<p>\n  The agreement includes $650 million upfront and up to $500 million in potential future milestone payments. \n</p>\n<p>\n  UCB expects to close the transaction by the end of the second quarter. \n</p>\n<p>\n  Column Group, a longtime Neurona investor, led a $23.5 million Series A funding announced in late 2015. Other investors have included Fidelity Management &amp; Research Co., UCB Ventures and Alexandria Venture Investments. \n</p>\n<p>\n  In December, South San Francisco-based Neurona presented results from ongoing Phase 1/2 trials evaluating NRTX-1001, a one-time, allogeneic inhibitory interneuron cell therapy for drug-resistant mesial temporal lobe epilepsy. The company said it continued to see durable seizure reduction from a single administration in most subjects. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 17, 2026 16:11 ET (20:11 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4211","symbol_name":"区域性银行","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2628781786","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2628781786","pubTimestamp":1776456660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"UCB agreed to buy Neurona Therapeutics for up to $1.15 billion, a deal that would add potential epilepsy drug NRTX-1001 to the Belgian company's portfolio.The agreement includes $650 million upfront and up to $500 million in potential future milestone payments.UCB expects to close the transaction by the end of the second quarter.Column Group, a longtime Neurona investor, led a $23.5 million Series A funding announced in late 2015. Other investors have included Fidelity Management & Research Co., UCB Ventures and Alexandria Venture Investments.In December, South San Francisco-based Neurona presented results from ongoing Phase 1/2 trials evaluating NRTX-1001, a one-time, allogeneic inhibitory interneuron cell therapy for drug-resistant mesial temporal lobe epilepsy. The company said it continued to see durable seizure reduction from a single administration in most subjects.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4211":"区域性银行","UCB":"美国社区银行","BK4539":"次新股","BK4139":"生物科技","BK4007":"制药","LENZ":"Therapeutics"},"translate_title":"UCB将以高达$1.15 B的价格收购Neurona Therapeutics","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"UCB":1.5},"content_text":"By Josh Beckerman \n\n\n \n\n\n  UCB agreed to buy Neurona Therapeutics for up to $1.15 billion, a deal that would add potential epilepsy drug NRTX-1001 to the Belgian company's portfolio. \n\n\n  The agreement includes $650 million upfront and up to $500 million in potential future milestone payments. \n\n\n  UCB expects to close the transaction by the end of the second quarter. \n\n\n  Column Group, a longtime Neurona investor, led a $23.5 million Series A funding announced in late 2015. Other investors have included Fidelity Management & Research Co., UCB Ventures and Alexandria Venture Investments. \n\n\n  In December, South San Francisco-based Neurona presented results from ongoing Phase 1/2 trials evaluating NRTX-1001, a one-time, allogeneic inhibitory interneuron cell therapy for drug-resistant mesial temporal lobe epilepsy. The company said it continued to see durable seizure reduction from a single administration in most subjects. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 17, 2026 16:11 ET (20:11 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}